Want to see TSE:SONA full AI Analyst Report?
SONA Stock Chart & Stats
C$0.36
C$0.01(4.84%)
At close: 4:00 PM EDT
C$0.36
C$0.01(4.84%)
Day’s Range― - ―
52-Week RangeC$0.26 - C$0.84
Previous CloseN/A
Volume13.05K
Average Volume (3M)49.22K
Market Cap
C$39.46M
Enterprise ValueC$32.88M
Total Cash (Recent Filing)C$52.76K
Total Debt (Recent Filing)C$328.87K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding114,375,250
10 Day Avg. Volume31,257
30 Day Avg. Volume49,223
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Nanorod TechnologyA proprietary nanorod platform aimed at improving diagnostic assay sensitivity could provide product differentiation in life-sciences applications. If commercialized successfully, the technology may support repeat material sales, licensing, or development partnerships across multiple assay formats.
Recent Financing Supports DevelopmentThe $2.53M financing provides resources to continue clinical development and fund working capital over the coming periods. Maintaining liquidity is important for a pre-revenue biotechnology company because it allows progress on commercialization activities before internally generated cash flows are available.
Modest Absolute DebtAbsolute debt remains modest at roughly $329K on a trailing-twelve-month basis, limiting the direct burden from borrowing costs relative to a heavily indebted balance sheet. This offers some financial flexibility, although negative equity still materially weakens the overall position.
Bears Say
No Commercial Revenue BaseThe absence of reported revenue means the business has not yet demonstrated commercial adoption or a self-sustaining sales engine. Persistent losses and negative EBITDA indicate that commercialization remains unproven, leaving future funding dependent on financing or successful product launches.
Accelerating Cash ConsumptionOngoing negative operating and free cash flow shows that the company cannot currently fund operations internally. The roughly 39% deterioration in TTM free cash flow versus the prior annual period suggests rising financing needs and greater execution pressure over the next several quarters.
Negative And Deteriorating EquityThe shift into negative equity materially reduces balance-sheet resilience and makes leverage measures more concerning despite modest debt. Declining total assets further limit financial flexibility, increasing dependence on additional capital and the risk of shareholder dilution.
Sona Nanotech Inc News
SONA FAQ
What was Sona Nanotech Inc’s price range in the past 12 months?
Sona Nanotech Inc lowest stock price was C$0.26 and its highest was C$0.84 in the past 12 months.
What is Sona Nanotech Inc’s market cap?
Sona Nanotech Inc’s market cap is C$39.46M.
When is Sona Nanotech Inc’s upcoming earnings report date?
Sona Nanotech Inc’s upcoming earnings report date is Sep 24, 2026 which is in 11 days.
How were Sona Nanotech Inc’s earnings last quarter?
Sona Nanotech Inc released its earnings results on Jun 29, 2026. The company reported -C$0.01 earnings per share for the quarter.
Is Sona Nanotech Inc overvalued?
According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued.
Does Sona Nanotech Inc pay dividends?
Sona Nanotech Inc does not currently pay dividends.
What is Sona Nanotech Inc’s EPS estimate?
Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sona Nanotech Inc have?
Sona Nanotech Inc has 114,375,250 shares outstanding.
What happened to Sona Nanotech Inc’s price movement after its last earnings report?
Sona Nanotech Inc reported an EPS of -C$0.01 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sona Nanotech Inc?
Currently, no hedge funds are holding shares in TSE:SONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sona Nanotech Inc
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.
Technical Analysis
BioMark Diagnostics
―
Eastwood Bio-Medical Canada
―
StageZero Life Sciences Ltd
―
Medmira
―
ZYUS Life Sciences
―